Biomarin is still expecting an EMA decision on hemophilia drug in H1 2022

The international pharmaceutical giant Biomarin is anticipating a decision in the first half of 2022 from the EMA about its candidate, Valoctocogene, meant to treat severe hemophilia. More information about the ongoing phase III trial with the drug will come in the New Year, says CEO.
by ULRICH QUISTGAARD, translated by Daniel Pedersen

Biomarin hopes to have a European approval of its potential new drug for the treatment of severe hemophilia A before summer 2022, the company reports in a press release in connection with its third quarter results.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading